U.S. Congressman Neal Dunn publicly recognized work related to MitoSense's research and development of treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Dunn specificly cited the U.S. Department of Veterans Affairs (VA) partnering with the private sector to find treatments for veterans suffering from such diseases.
Ealier this year in January, MitoSense entered into a Cooperative Research and Development Agreement (CRADA) with the VA to study mitochondrial transplantation treatments for ALS patients. MitoSense particularly noted the benefit of working with scientists at James A. Haley Veterans Hospital because it treats the most ALS patients of any hospital in the entire VA system.
Congressman Dunn's official remarks are below and can be found here.
IN RECOGNITION OF ALS RESEARCH AT THE DEPARTMENT OF VETERANS AFFAIRS ______ HON. NEAL P. DUNN of florida in the house of representatives Tuesday, April 26, 2022 Mr. DUNN. Madam Speaker, as the son of a veteran, father of a veteran, and a veteran myself, I rise in support of important work being done at the Department of Veterans Affairs (VA) regarding research and development of treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. This work is combining the capabilities of National Polytrauma Centers, like the James A. Haley Veterans' Hospital in Tampa, Florida, with the expertise of the private sector to give hope to veterans who are battling these illnesses, everywhere. Veterans are 60 percent more likely to be diagnosed with ALS compared to the general population. More research needs to be done to understand the connection, which goes back at least 100 years, between military service and ALS, as well as to ensure we are able to achieve the best possible outcomes for our veterans. I applaud the VA for continuing to make this a priority and look forward to seeing the potential of these partnerships.